About ABV-1703 for Pancreatic Cancer
Product Overview
The global pancreatic cancer treatment market is expected to reach USD 4.2 billion in 2025, according to a new report by Grand View Research, Inc. Growing awareness of the availability of various treatment options has helped to propel the market growth at a global level. The peak incidence of pancreatic cancer is seen in the age group of 65 to 75 years. Furthermore, pancreatic cancer is expected to be the second common cause of death in the U.S. by 2030. Together, these factors will support market growth in the forecast period.
ABV-1703 shares the same API, extract from Grifola frondosa Maitake mushroom, and immune-modulation effects in peripheral blood as ABV-1501. A Phase II Study of ABV-1703 combined with Gemcitabine monotherapy in patients with advanced inoperable or metastatic pancreatic cancer was approved by U.S. FDA in 2017. We are engaging Andrew E. Hendifar, MD of Cedars-Sinai Medical Center, to conduct the Phase II clinical trial.
INDICATED USE
- Pancreatic Cancer
DEVELOPMENT PARTNERS
- Cedars-Sinai Medical Center
DEVELOPMENT STATUS
- 2017: US FDA IND approved (Phase II Trial)
- 2021: Initiating Phase-II Trial
PATENT STATUS
- Patent Granted in the United States, Great Britain, Japan, Germany, France, Italy, China, and Taiwan
TOXICOLOGY
- No dose-limiting toxicity encountered
CLINICAL TRIAL
- Phase II study to be initiated in Q4 2020
CROSS REFERENCE
- BioLite IND# 129575 (TNBC)
- ND#131300 (MDS)
- MSKCC IND# 68853
SAFETY
- ABV-1703 has been used for more than 10 years as functional food
ABV-1703 Development Timeline
DISCLAIMER: Clinical trials may be in early stages. There is no guarantee that any specific outcome will be achieved. Investments may be speculative, illiquid and there is a risk of loss. Past performance is not indicative of future results.